MEDICINOVA INC MNOV Cash Flow

Medicinova inc (MNOV)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13
Operating activities:
Net loss
-10,958	-12,941	-11,165	-15,566	-14,829	-14,675	-16,070	-13,045	-12,689	-11,163	-11,009	-10,090	-10,500	-10,865	-12,152	-10,924	-10,011	-8,845	-8,490	-9,222	-9,057	-9,195	-3,401	-3,297	-3,961	-4,028	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation
2,009	4,112	3,164	7,518	6,499	6,330	9,105	5,900	5,837	4,474	3,462	3,131	3,701	3,972	4,843	3,734	2,951	2,025	1,797	2,211	1,896	1,638	1,481	1,181	1,313	1,216	0	0	0
Amortization of Kissei upfront payment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	0	0	0
Depreciation and amortization
22	23	24	24	25	25	26	27	27	28	24	20	17	14	14	16	21	26	32	37	39	40	39	53	77	100	0	0	0
Gain on disposal of assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	0	0	0
Change in joint venture investment
-	-	-	-	-	-	-	-	-	-1	-14	-18	-34	-32	-28	-44	-33	-34	-29	-3	4	3	0	0	0	-	-	-	-
Changes in assets and liabilities:
Prepaid expenses and other assets
0	-	0	0	0	-	-105	-20	-49	-242	-218	-234	-120	-175	-192	-333	-474	284	195	133	13	-1,186	356	474	656	1,353	0	0	0
Receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,008	0	0	0	-	-	-	-
Accounts payable, accrued liabilities and other liabilities
628	194	144	478	194	-663	90	170	72	1,246	353	86	-45	127	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued expenses and deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-18	130	-82	-509	0	0	0
Accrued compensation and related expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	105	-66	65	-41	0	0	0
Net cash used in operating activities
-8,974	-9,124	-8,364	-8,060	-8,062	-9,114	-8,516	-8,700	-8,458	-6,923	-6,936	-6,599	-6,674	-6,546	-7,004	-6,591	-6,338	-7,152	-6,668	-7,089	-7,185	816	-2,172	-2,487	-3,256	-10,646	0	0	0
Investing activities:
Acquisition of property and equipment
11	11	4	4	3	10	0	0	0	-	-	-	-	84	0	0	0	-	-	-	-	3	0	0	0	-	-	-	-
Proceeds from issuance of equity awards under ESPP
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0
Net cash used in investing activities
-11	-11	-4	-4	632	626	0	0	0	-	-	-	-	-84	0	0	0	-	-	-	-	-3	-15	-0	-45	-36	0	0	0
Financing activities:
Proceeds from sales of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	0	0	0
Proceeds from issuance of common stock, exercise of common stock options and warrants, net of issuance costs
7,088	10,588	8,772	5,599	7,663	42,757	45,745	49,305	49,725	10,719	6,452	2,876	652	8,577	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of equity under ESPP
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	3,934	13,387	13,363	0	0	0
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from issuance of equity awards under ESPP
16	27	27	40	40	51	51	40	40	77	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
7,105	10,615	8,799	5,639	7,703	42,808	45,796	49,345	49,765	10,797	6,529	2,979	755	8,665	8,412	24,601	24,901	17,563	18,351	2,182	1,481	4,162	3,463	3,964	15,053	13,370	0	0	0
Effect of exchange rate changes on cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	0	1	3	0	-11	-3	-0	6	18	10	5	-1	-4	-7	-7	-6	0	0	0	-	-	-	-
Net change in cash and cash equivalents
-1,879	1,479	430	-2,424	270	34,321	37,906	41,272	41,302	3,873	-436	-3,675	-5,981	2,041	1,359	17,984	18,544	10,407	11,675	-4,915	-5,710	4,968	1,276	1,479	11,755	2,689	0	0	0
Supplemental disclosure of cash flow information:
Income taxes paid
-	-	-	-	-	-	-	-	-	9	9	8	8	6	6	5	5	7	7	7	7	5	5	6	6	6	0	0	0